Work

Old problems, new tools: ZR2 in older patients with DLBCL

Year: 2025

Type: article

Abstract: unique to MCL or also seen in other types of lymphoma resistant to BTK inhibitors.Nonetheless, this work could mark the start of a new era of understanding resistance to BTK inhibitors in MCL, moving beyond genetic alterations.More research is needed to understand what triggers giant cell formation and any liabilities this creates that could be leveraged for more effective combination therapies.This could allow BTK inhibitor therapy to be more effective in a broader swath of patients with MCL and for a longer response duration among those who do respond to treatment.

Source: Blood

DOI: 10.1182/blood.2025030855

Authors: A. Vera de Jonge, Martine E. D. Chamuleau

Institutions: Amsterdam University Medical Centers, Cancer Center Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4416425680